

de
cl
ck
B
CMT

contacting said product, serum-free cell cultures or serum-containing cell cultures with the cyclic lipopeptide, salt of the lipopeptide, ester of the lipopeptide, or mixture thereof [salts or esters thereof, or mixtures of the same] as an inactivating agent, [and inactivation is performed] at room temperature [within from] for 30 minutes up to 2 hours [at maximum], wherein

a) the agent is added to said products at a concentration of 1-100 μ M when inactivating viruses in the products; and wherein

b) the agent is added to [the] serum-free culture medium at a concentration of 1-65 μ M, or to [the] serum-containing culture medium at a concentration of 10-100 μ M, when inactivating viruses in cell medium [cultures].

Claim 2, lines 2-3, delete "or biotechnological",

Line 4, delete "preferably 30-60°C,".

B²

3. (Amended) The method according to claim 1, characterized in that the cyclic lipopeptide is a naturally occurring, or a chemically synthesized lipopeptide [lipopeptides, as well as those] or a lipopeptide produced or modified by genetic engineering [are used as cyclic lipopeptides].

Claim 4, line 6, after "formula I" insert --,--.

Claim 5, line 2, replace "compounds of the general formula I with" with --C₁₀₋₁₂ is a--,

Line 3, delete "are used".

Claim 6, line 3, delete "preferably monoesters".

Claim 9, line 2, after "human and" insert --non-human--.

D² B³

10. (Amended) The method according to claim 1 characterized in that one or more viruses selected from the group consisting of herpes viruses, [preferably HSV-1, HSV-2, BHV-1 and SHV-1,] immunodeficiency viruses, [preferably HIV-1, HIV-2, SIV_{agm}, the] vesicular stomatitis virus (VSV), and [the] Semliki-Forest virus (SFV) are inactivated.

Claim 11, Line 1, replace "New lipoheptapeptides" to --Lipoheptapeptides--.

Please add the following new claims.

--13. The method of claim 2, wherein the temperature is 30-60 °C.

14. The method of claim 6, wherein the esters are monoesters.

B⁴ C²

15. The method of claim 10, wherein the herpes viruses is herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2), bovine herpes virus type 1 (BHV-1) or suid herpes virus type 1 (SHV-1).

16. The method of claim 10, wherein the immunodeficiency virus is human